Epidemiology, Staging, and Management of Multiple Myeloma
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index; 21 of the 61 sources its claims cite were checked for support.
Abstract
Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the global proportion). Incidence has risen by 126% globally and over 40% in the US since 1990, while global mortality has risen by 94% and US mortality has fallen by 18%. The 5 year survival in the US has more than doubled over the past decades with the introduction of new targeted therapies and transplant techniques. Risk factors for MM include age (average age of diagnosis is 69), race (African Americans are over double as likely to be diagnosed), sex (men are at a 1.5× risk), and family history. Diagnosis includes serum or urine electrophoresis and free light-chain assay but requires bone marrow biopsy. It is distinguished from smoldering myeloma and monoclonal gammopathy of undetermined significance by a high (>3 g/dL) level of M-protein (monoclonal light chains) and the presence of CRAB (Hypercalcemia, Renal failure, Anemia, Bone pain) symptoms, which include hypercalcemia, renal failure, anemia, and bone pain, suggesting an end-organ damage. International staging system staging involves beta 2 microglobulin and albumin levels, while the revised system considers prognostic factors such as lactate dehydrogenase levels and chromosomal abnormalities. Front-line management includes induction regimen, maintenance therapy and hematopoietic cell transplantation for eligible patients and bisphosphonates or bone-stimulating agents for the prevention of skeletal events. Treatment for relapsed disease includes newly approved monoclonal antibodies like the CD38-targeting daratumumab, proteasome inhibitors, immunomodulating agents, and investigational therapies such as B cell maturation antigen Chimeric antigen receptor T cells.
Overview
CoChat Summary
## TL;DR
This 2021 review summarizes the epidemiology, staging, diagnosis, and management of multiple myeloma, emphasizing that incidence has risen while survival has improved with newer therapies and transplant techniques. It also highlights the major risk groups, current staging systems, and common first-line and relapsed-disease treatment approaches.
## Key findings
- Global MM burden was estimated at 160,000 cases in 2018 and 106,000 deaths in 2018; MM accounted for 0.9% of all cancer diagnoses and 1.1% of all cancer deaths.
- From 1990 to 2016, global incidence increased by 126% and global deaths increased by 94%; in the US, incidence rose by 143% since 1975, while mortality fell and 5-year survival increased from 23.7% in 1976 to 53.9% in 2016.
- Risk is higher in older adults (median diagnosis age 69 in the US), men (about 1.5× higher risk globally), and African Americans (incidence 16.5/100,000 in African American men and 12.0/100,000 in African American women, versus 8.2 and 5.0 in Caucasians).
- In an international clinical trial with 3,060 participants, 5-year survival by revised ISS stage was 82% for stage I, 62% for stage II, and 40% for stage III.
## Methods
- Narrative review article describing the “latest review” of MM; the paper states that an extensive literature search was done.
- Synthesizes epidemiologic data (e.g., GLOBOCAN, SEER), staging systems (ISS, DSS, revised ISS), diagnostic criteria, and treatment evidence from cited trials and studies.
- Main analysis is descriptive and integrative rather than experimental, comparing published incidence, mortality, risk-factor, staging, and treatment results.
## Limitations
- The paper does not report a systematic review method, search strategy, or inclusion/exclusion criteria; this is evident from the text (descriptive review), not stated as a limitation by the authors.
- The evidence base is largely observational and from cited studies/trials across different settings, so direct causal inference is limited; this is evident from the text.
- Not stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Map showing the estimated age-standardized incidence rates per 100,000 (world) in 2018 of multiple myeloma (MM) for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/53cda705514b4aeea933ce5143d2fbf3/epidemiology-staging-and-management-of-multiple-myeloma-figure-1.jpg)
![Figure 2 Map showing the estimated age-standardized mortality rates per 100,000 (world) in 2018 of multiple myeloma for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/0a44533b89b8450397215c10f72e1fcc/epidemiology-staging-and-management-of-multiple-myeloma-figure-2.jpg)
![Figure 3 Graph showing the estimated cumulative risk of incidence in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/525138bbaf0842a7aaa427b870ecd122/epidemiology-staging-and-management-of-multiple-myeloma-figure-3.jpg)
![Figure 4 Graph showing the estimated number of prevalent cases (5 year) as a population in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2 Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/6e96994452ec4de28c61f038e43ff651/epidemiology-staging-and-management-of-multiple-myeloma-figure-4.jpg)
![Figure 5 Bar chart showing the 5 year age-adjusted mortality rates from 2013–2017 by age for the United States. Created with Tableau 2019.2. Data source: SEER*Explorer [11].](https://figures.cochat.ai/paper-figures/82c4eb6e362047998968d2004b611456/epidemiology-staging-and-management-of-multiple-myeloma-figure-5.jpg)
![Figure 6 Bar chart showing the United States’ 5-year age-adjusted mortality rates from 2013–2017 for all races (including Hispanics). Created with Tableau 2019.2. Data source: SEER*Explorer [11].](https://figures.cochat.ai/paper-figures/b8ccac5b620b49deb4385d0716c909bd/epidemiology-staging-and-management-of-multiple-myeloma-figure-6.jpg)

Verification
Claims the paper makes
15 Valid · 12 Not valid · 29 Not checked · 10 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“KRd instead of VRd can be used as initial therapy in patients with t(4;14), t(14;16), t(14;20), and those with ≥2 high-risk abnormalities based on the results of phase 2 studies suggesting higher complete response (CR) rates and minimal residual disease negativity rates compared with historical results using VRd [28,30,31].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Disputedcites [28] Rajkumar, 2011, Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management, Am. J. Hematol. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
- Not checked yetcites [30] Rajkumar, 2010, Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management, Am. J. Hematol. source
Checked before — its earlier verdict is held back until a new check runs.
- Not checked — no full text of the sourcecites [31] Sheng, 2017, Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials, Eur. J. Haematol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Suggested underlying factors include discrepancies in health-risk behaviors, such as smoking and alcohol consumption, and higher rates of obesity among men, though none of these risk factors have been proven in MM [9].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 2. Epidemiology > 2.3. Risk Factors
What the sources say
- Partly supportedcites [9] Cowan, 2018, Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016, JAMA Oncol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says there is a “lack of known strong risk factors for myeloma,” which supports the claim’s general caution. It does not assess smoking, alcohol consumption, or obesity individually, or identify them as explanations for higher rates among men. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The revised international staging system (RISS) combines elements of tumor burden (ISS) and disease biology [23].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.2. Staging
What the sources say
- Supportedcites [23] Palumbo, 2015, Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J. Clin. Oncol. source
The Introduction describes an ISS marker as reflecting tumour mass and identifies chromosomal abnormalities as biological features of multiple myeloma. The Discussion states that R-ISS combines ISS staging, chromosomal abnormalities and serum LDH, supporting the paraphrase. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Those undergoing HCT typically receive a triplet regimen for 3–4 months prior to stem cell collection in order to reduce tumor cell numbers in the bone marrow.”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Could not verifycites [33] Chim, 2018, Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond, Leukemia sourceExperimental — accuracy not yet measured
The 'Role of salvage ASCT' section discusses re-induction before a second transplant, and the 'Proposed treatment algorithm' section prefers triplets for relapsed myeloma. Neither addresses a typical 3–4-month triplet regimen before stem-cell collection to reduce tumor cells in the bone marrow; searches for that timing and purpose found no supporting passage. Page numbers were unavailable in our copy. (LLM, conf=0.76)
- Partly supportedcites [34] Laubach, 2016, Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group, Leukemia sourceExperimental — accuracy not yet measured
Our copy supports the general idea that transplant-bound relapsed patients are treated with multi-drug regimens before harvest: 'General management' states that patients with high-risk/aggressive disease 'are generally treated with highly active three-or four-drug combinations to achieve maximal response' and that responders 'can then be considered for ASCT', and 'AUTOLOGOUS STEM CELL TRANSPLANTATION' notes that 'mobilization after reinduction using various mobilization regimen... is feasible' when a new stem cell collection is needed. However, no passage in our copy specifies a 3-4 month duration of pre-harvest therapy, nor does it state that the purpose of giving it before collection is to reduce tumour cell numbers in the bone marrow; the paper frames the three-drug approach as achieving maximal response in high-risk disease and explicitly leaves one- versus two- versus three-drug choice unsettled for indolent relapse. The quantitative and rationale components of the claim are therefore not attributable to this source. (LLM, conf=0.68)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low-dose dexamethasone (i.e., once weekly 40 mg dose) is associated with less dexamethasone-related toxicity than more intensive dosing scheme without compromising efficacy [48].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Partly supportedcites [48] Rajkumar, 2010, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial, Lancet Oncol. sourceExperimental — accuracy not yet measured
The Methods (Procedures; page unavailable) specify 40 mg dexamethasone once weekly in the low-dose arm. The Results and Discussion report less toxicity and no worse progression or survival outcomes with low-dose treatment, but the Results also find a significantly lower response rate after four cycles (68.3% versus 79%). Thus, “without compromising efficacy” is too broad, and the evidence is limited to treatment with lenalidomide in newly diagnosed myeloma. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
15 more claims · 1 with their cited sources checked
Create a free account to see all 66 claims and to verify the 18 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Multiple myeloma affects men more than women (3:2 ratio). 5,6”
From Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2024) · cites this paper as [5]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · cited 3×
“5 mg/L, and Stage II for all those in between [19].”
BackgroundInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210 · cited 1×
“The revised international staging system (RISS) combines elements of tumor burden (ISS) and disease biology [23].”
MethodBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · cited 1×
“Albeit weak, there is data suggesting that use of a proteasome inhibitor may abrogate the prognostic impact of at least some of these high-risk genetic markers [32].”
BackgroundDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“The recently approved monoclonal antibody, daratumumab, which targets CD38 (a re ceptor highly expr sed on myeloma cells), has become a favorite for later line induction regimens [35,36].”
BackgroundRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · cited 1×
“, once weekly 40 mg dose) is associated with less dexamethasone-related toxicity than more intensive dosing scheme without compromising efficacy [48].”
BackgroundMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908 · cited 1×
“, bortezomib, lenalidomide, dexamethasone) improved response rates, depth of response, progression-free survival, and overall survival compared with the then approved front-line regimen Rd (lenalidomide, dexamethasone) making a three-drug regimen the main stay of initial therapy for most patients with MM [25].”
Background
Research works printed but not linked: 3
- Howlander, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2019). SEER Cancer Statistics Review 1975–2016.
- Vakiti, A., Padala, S.A., and Mewawalla, P. (2020, May 07). Myeloma Kidney, Available online: https://www.ncbi.nlm.nih.gov/books/NBK499952/.
- Vakiti, A., and Mewawalla, P. (2020, May 07). Malignancy-Related Hypercalcemia, Available online: https://www.ncbi.nlm.nih.gov/books/NBK482423/.
Cited by
Items 201–300 of 331
Fathy, M. G. Y. A., Nasr, E., & Metwally, E. A. (2023) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2023.305536 · Cited by 1
“When it comes to the CRAB factors, very little is known about how their relationships to survival actually work (11) .”
BackgroundResultInfluentialPerillo, T., D’Agostino, V., Pagano, A., Serino, A., & Manto, A. (2023) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2023.06.006 · Cited by 1
Is surgical indication in multiple myeloma a poor prognosis sign? SEER database analysis
Öztürk, R., Amer, K. M., Gençoğlu, A. T., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03273-8 · Cited by 1
“Again, according to statistics, the age-standardized incidences of males and females are 2.1 and 1.4 per 100,000 people with multiple myeloma, respectively, and the number of the age-standardized deaths in males and females is 1.3 and 0.9 per 100,000 patients, respectively [16].”
InfluentialPolski, A. G., Marquez, J. R., & McQuiston, S. A. (2023) · Cureus · doi:10.7759/cureus.43040 · Cited by 1
“5 times the risk of females, and individuals of African descent are the highest risk demographic, at greater than two times the risk of individuals of European descent, with even greater risk when considering early onset presentation MM [2].”
BackgroundFei, H., Shi, X., Li, S., Li, Y., Yin, X., Wu, Z., Wang, W., Shi, H., & Li, R. (2023) · Tissue and Cell · doi:10.1016/j.tice.2023.102263 · Cited by 1
Ballas, L., Ailawadhi, S., Narang, M., Gasparetto, C., Lee, H. C., Hardin, J. W., Durie, B. G. M., TOOMEY, K. E., Omel, J. L., Wagner, L. I., et al. (2023) · Practical Radiation Oncology · doi:10.1016/j.prro.2023.11.004 · Cited by 1
Positron Emission Tomography/Computed Tomography Transformation of Oncology
Murtazaliev, S., Rowe, S. P., Sheikhbahaei, S., Werner, R. A., & Sólnes, L. B. (2024) · PET Clinics · doi:10.1016/j.cpet.2023.12.010 · Cited by 2
Shawahna, R., Amer, R. A., Salameh, H. T., Shawahna, A.-R., Aljondy, M., & Zain-Aldain, M. (2024) · BMC Cancer · doi:10.1186/s12885-024-12024-z · Cited by 2
“For the diagnosis of multiple myeloma, the following procedures, laboratory testing, and imaging should be performed or ordered [1, 16, 29–36]: (1) history and physical examination, (2) bone marrow examination to look for clonal plasma cells, biopsy-proven bone, or soft tissue (extramedullary)…”
BackgroundMethodInfluentialEducational Case: Multiple myeloma
Givi, J. P., Williams, N. A., Hass, R., Tacker, D. H., Goswami, A., & Randall, C. (2024) · Academic Pathology · doi:10.1016/j.acpath.2024.100117 · Cited by 1
Shokripour, M., Hosseini, S. E., Omidifar, N., Mokhtari, M., & Safaei, A. (2024) · PubMed Central · doi:10.30476/ijms.2023.96892.2855 · Cited by 1
Gonzaga, A. K. G., Morais, H. G. D. F., Oliveira, C. D. M., et al. (2024) · Imaging Science in Dentistry · doi:10.5624/isd.20240032 · Cited by 1
Mimicking Multiple Myeloma: The Importance of the Differential Diagnosis
Derudas, D., Concu, C., Durzu, T., Piras, D., Nemolato, S., Liguori, A., Simula, M. P., & Nasa, G. L. (2024) · Archives of Clinical and Medical Case Reports · doi:10.26502/acmcr.96550683 · Cited by 1
“Multiple myeloma (MM) is a neoplastic disease due to the proliferation of clonal plasma cells and accounts for 15% of hematologic neoplastic tumors [1,2].”
BackgroundTan, C. J., Kacerek, D., Kampirapawong, N., Godara, A., & Chaiyakunapruk, N. (2025) · Cancer Medicine · doi:10.1002/cam4.70585 · Cited by 7
Evaluation of the antiangiogenic effect of AMG232 in multiple myeloma coculture systems
Pooraskari, Z., Ghazani, H. B., Piri, R., Habibi, S., & Shahidi, M. (2025) · Medical Oncology · doi:10.1007/s12032-025-02659-8 · Cited by 1
“Multiple myeloma (MM) is defined by the abnormal growth of immunoglobulin-producing plasma cells in the bone marrow (BM) and is the second most common hematologic malignancy [1].”
Impact of Social Vulnerability Index on Multiple Myeloma Mortality
Tan, J. Y., San, B. J., Ong, T. E., et al. (2025) · Oncology · doi:10.1159/000545459 · Cited by 1
When should I use filgrastim after autologous transplantation in MM patients?
Arslan, S., Berber, İ., Kuku, İ., Kaya, E., Erkurt, M. A., Biçim, S., Kaya, A., & Pinar, A. (2025) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2025.104171 · Cited by 1
An improved procedure for synthesis of lenalidomide as an active pharmaceutical ingredient
Ataollahi, E., Sadeghpour, H., Zamani, L., & Khabnadideh, S. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102625 · Cited by 2
Management of Renal Failure in Multiple Myeloma
Derudas, D., & Concu, C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105444 · Cited by 2
Tu, S.-K., Li, M., Hu, M. I.-N., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3055773/v1 · Cited by 1
Ohlstrom, D. J., Pilcher, W., Michaud, M. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.27.656392 · Cited by 1
Murkamilov, I. T., Айтбаев, К. А., Kudaibergenova, I., Fomin, V. V., Абдилалимовна, М. Ж., & Yusupov, F. A. (2021) · Bulletin of Science and Practice · doi:10.33619/2414-2948/65/22 · Cited by 1
Myeloma multiplex treatment and overall survival
Balkanov, S. K., Трајкова, С., Stavric, S. G., Pivkova-Veljanovska, A., Labacevska, M. P., Spasovski, D., Rambabova‐Bushljetik, I., Kalcev, G., & Stavridis, I. P. (2021) · Macedonian Pharmaceutical Bulletin · doi:10.33320/10.33320/maced.pharm.bull.2021.67.01.008
“In USA and Europe, the incidence of MM is 3 to 4 per 100,000 people (Becker, 2011; Padala et al., 2021; Vélez et al., 2016).”
BackgroundCai, Z., Li, Y., He, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1319734/v1
Silberstein, A. E., Fiala, M. A., Loh, K. P., Cordner, T., Mian, H. S., & Wildes, T. M. (2022) · medRxiv · doi:10.1101/2022.05.30.22275780
Elsayed, D., Ashby, C., Wardell, C. P., van Rhee, F., Ussery, D. W., Zhan, F., & Bauer, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1954260/v1
Al-Anazi, K. A., Mutahar, E. Y., Abduljalil, O., Kanfer, S., Kaloyannidis, P., Estanislao, A., Apostolidis, I., Almokhtar, N., Darweesh, M., Abdulbaqi, M., et al. (2022) · Journal of Stem Cell Therapy and Transplantation · doi:10.29328/journal.jsctt.1001027
“In patients with MM who are eligible for autologous HSCT, 3-4 cycles of induction therapy that consists of either bortezomib, lenalidomide, dexamethasone (VRd) or bortezomib, cyclophosphamide, dexamethasone (VCd), or bortezomib, thalidomide, dexamethasone (VTd) are usually given followed by single autologous HSCT [5,8…”
BackgroundInfluentialGhanem, B., & Shi, L. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01215-w · Cited by 1
“The estimated incidence rate of MM in the US is about 7 cases per 100,000 [13].”
BackgroundMyeloma Multipel pada Pasien dengan Fraktur Patologis: Laporan Kasus
Githa, I. P. A. R., & Rheja, A. A. D. A. (2022) · Intisari Sains Medis · doi:10.15562/ism.v13i3.1521 · Cited by 1
EIbodeng, G. O., Fatola, A., & Galeas, J. N. (2022) · Journal of Case Reports and Images in Oncology · doi:10.5348/100116z10gi2022cr
COVID-19 INFECTION IN PATIENTS WITH MULTIPLE MYELOMA (REVIEW ARTICLE)
Galanin, V. V., Демко, И. В., Ивановна, Б. В., Gordo, A. A., Белоногов, Д. В., & Kochergina, E. S. (2022) · Bulletin of Medical Science · doi:10.31684/25418475-2022-4-116
Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies
Al‐Anazi, K. A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109279
An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
Al‐Anazi, K. A., Alshaibani, Z., & Kalogiannidis, P. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109059
Li, M., Guo, Q., Shi, Q., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2765409/v1
Wang, Y., Yang, Y., Wang, W., Li, J., Xu, T., & Liu, P. (2023) · Research Square · doi:10.21203/rs.3.rs-2941538/v1
Comparison of eGFR formulas (CKD-EPI and MDRD) in patients with multiple myeloma
Erinç, O., Yesilyurt, S., & Nalçacı, M. (2023) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1222031
Xiao, Y., Chang, W., Jiang, H., et al. (2023) · Science of Advanced Materials · doi:10.1166/sam.2023.4502
Plasma cell myeloma: Pendekatan diagnosis dari aspek kliniko-morfologik dan imunofenotipe
Angelina, A., & Retnani, D. P. (2023) · Jurnal Klinik dan Riset Kesehatan · doi:10.11594/jk-risk.02.2.5
Daratumumab: A Drug with Transfusion Dilemma
Biswas, A. K., Gairola, A., Baranwal, A. K., Jagani, R., Pawar, A., & Dimri, U. (2023) · Global Journal of Transfusion Medicine · doi:10.4103/gjtm.gjtm_36_23
Extramedullary myeloma in the soft tissues of the arm
Karupakula, E. (2023) · Radiopaedia.org · doi:10.53347/rid-178633
Xi, X., Xu, R., Li, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3660067/v1
Cassataro, G., Smorlesi, G., Miceli, G., et al. (2023) · American Journal of Medical and Clinical Sciences · doi:10.33425/2832-4226/23011
Etxebeste, A. (2023) · Depósito Académico Digital Universidad de Navarra (University of Navarra) · doi:10.15581/10171/69185
Multiple Myeloma Presenting With Bronchopneumonia: A Case Report
Karnan, A., Ghewade, B., Alone, V. D., & Ledwani, A. (2024) · Cureus · doi:10.7759/cureus.56010
Survivorship among patients with haematological cancer: Work disability, dementia, and neuropathy
Maksten, E. F. (2024) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau705524384
A young patient with cord compression diagnosed as a solitary sacral plasmacytoma: a case report
Dissanayaka, I., Karunarathna, W., & Weerawansa, P. (2024) · Anuradhapura Medical Journal · doi:10.4038/amj.v18i1.7797
MOHAMED, M. D. D. M. S. K. S., Marei, Y. M., Mohamud, H., et al. (2024) · Egyptian Journal of Hematology and Bone Marrow Transplantation · doi:10.21608/ejhbmt.2024.352663
“…which shows that circulating transgelin concentrations predict long-term irreversible kidney insufficiency in patients with MM. Woziwodzka et al. [18] reported that several immunoglobulins was identified where IgG in 92 (73) patients, IgM in 2 (2) patient, IgA in 23 (18) patients, κ in 79 (63)…”
BackgroundResultInfluentialОстровский, В. К. (2024) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.24.2.213
“Додатковим фактором, який поте-нціює ризик виникнення ІМ у даних пацієнтів є розвиток метапластичної анемії, яка, в свою чер-гу, призводить дисбалансу між доставкою та по-требою міокарда в кисні [2, 7].”
Multiple Myeloma with Concurrent Pericardial Effusion
Mills, K., Jaber, H., Jahansooz, A., & Ablah, E. A. (2024) · Kansas Journal of Medicine · doi:10.17161/kjm.vol17.21630
Røllum-Larsen, J., Engell, A. E., Diaz‐delCastillo, M., Heegaard, A., & Jørgensen, H. L. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05822-9
Clinical and economic studies of pharmacotherapy for multiple myeloma: literature review data
Лучинин, Е. А., Zhuravleva, M. V., Shelekhova, T. V., Александрович, К. К., & Валентиновна, Л. Е. (2024) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2024-5-2-38-47
Yan, M.-X. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i22.5196
A rare case of multiple myeloma with several atypical manifestations
Nasti, C., Natale, R., Morena, A., Pepa, R. D., Pasanisi, F., & Santarpia, L. (2024) · Italian Journal of Medicine · doi:10.4081/itjm.2024.1760
A Case Report of the Atypical Presentation of Multiple Myeloma Manifesting as a Sternal Mass
Kaushik, H., Manuja, N., Devde, K. D., & Dongre, A. S. (2024) · Cureus · doi:10.7759/cureus.65004
Zelluläre Therapien im Alter: Everything, everywhere, all at once?
Rösler, W. (2024) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-024-0642-x
Kerna, N. A., Pruitt, K. D., Carsrud, N. D. V., Ngwu, D. C., Kadivi, K., Holets, H. M., Flores, J. V., Alozie, U. G., Senat, A. J. B., Azi, C. I., et al. (2024) · European Journal of Medical and Health Research · doi:10.59324/ejmhr.2024.2(5).02 · Cited by 1
Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy
Cabrera, M. E., Peña, C., Vega, V., Rojas, H., Pizarro, Á., Rojas, C., Calderon, S., Oliva, J., Hales, C., Rojas, B., et al. (2024) · Cancer Reports · doi:10.1002/cnr2.2126
“Most notably, the female gender predominate also in multiple myeloma in Chile [38, 39], unlike what is described in the literature [40, 41].”
BackgroundNassar, I. G. I., Saad, M. A., Elkholy, R. A., & Allam, A. A. (2024) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_21_24
Mostafa, N. N., El-Ghammaz, A. M. S., Abulmaged, D. F. A.-G. M., & Abdalla, N. E.-H. H. (2024) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_62_23
Soloveva, M. V., Solovev, M. V., Kovrigina, A. M., & Менделеева, Л. П. (2025) · Journal of Modern Oncology · doi:10.26442/18151434.2024.4.203086
Assessment of the serum level of Endothelin-1 in patients with multiple myeloma
Naguib, M. G., Hassan, E. A. E. W., Moussa, M. M., et al. (2025) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_85_24
Wang, Y., Lan, T., Zhou, C., Xu, T., & Liu, P. (2025) · Clinical Cancer Bulletin · doi:10.1007/s44272-025-00031-5
“At present, most of the studies on the staging and prognosis of myeloma pay more attention to the cytogenetics of patients [8], while the prognostic value of many other clinical parameters has been ignored.”
Dong, R., Liu, R., Yang, R., Yang, Y., Xu, Y., Lei, B., Zhao, W., Zhang, W., Gao, G., He, A., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02448-9
“MM accounts for about 10% of hematological malignancies and its incidence is gradually increasing [27, 28].”
Painful swelling of the skull as the first symptom of multiple myeloma – a case report
Sadowski, J., Roszak, M. Ł., Kipiński, L., Kandziora, K., Szczerbaniewicz, A., Żabicka, I., & Labuz-Roszak, B. M. (2025) · Polski Merkuriusz Lekarski · doi:10.36740/merkur202502119
Quach, H., Kım, K., Wong, R. S. M., Tan, S. Y. M., Wang, M., Chang, K., Braunlin, M., Talpes, M., Najdi, R., & Kim, J. S. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.05.001 · Cited by 1
Qudratullah, Tariq, M., Rehman, I. U., et al. (2025) · INNOVAPATH · doi:10.63501/08meax47
Multiple myeloma associated with diffuse pulmonary calcifications: pathomorphological study
Volos, L. I., & Stoliar, H. L. (2025) · Morphologia · doi:10.26641/1997-9665.2024.4.6-14
Periportal Collar Sign: A Potential Sonographic Pattern of Multiple Myeloma
Farina, R., Lionetti, F., Foti, P. V., et al. (2025) · Journal of diagnostic medical sonography · doi:10.1177/87564793251343870
“12 According to the Global Cancer Observatory statistics, in 2018, there were approximately 160 000 cases of multiple myeloma globally, accounting for 0.9% of all cancer diagnoses.”
InfluentialTypes of anemia in hematological malignancy
Al-Jameel, I. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20251622
Memiş, F., Kandefer, M. Y., Aydın, S., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15131641
Epidemiological Characteristics of Multiple Myeloma in the Republic of Crimea
Kaliberdenko, V. B., Наримановна, У. А., Ametova, L. O., Рустамовна, К. Э., & Yakushev, D. A. (2025) · I P Pavlov Russian Medical Biological Herald · doi:10.17816/pavlovj624305
Jolec, L., Bechade, C., Lanot, A., et al. (2025) · Peritoneal Dialysis International · doi:10.1177/08968608251357226
Achalasia: A Rare Manifestation of Multiple Myeloma - A Case Report
Sumarpo, A., Gunawan, C. K., Supriadi, V., et al. (2025) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3212
Zhou, H., Zhang, M., Jin, Y., & Lang, X. (2025) · Hematology · doi:10.1080/16078454.2025.2532893
“Epidemiological data reported by Padala SA et al. indicate a 126% increase in the global incidence of MM and a 94% rise in its mortality rate since 1990 [4].”
Perrone, V., Leogrande, M., Giacomini, E., Cappuccilli, M. L., & Esposti, L. D. (2025) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s529788
Cai, H. (2025) · American Journal of Translational Research · doi:10.62347/zgyb9556
Tao, Y., Yuan, L., Ding, Y., Xie, R., Liu, F., Zhang, Z., Xu, X., & Wang, X. (2025) · Biomedicines · doi:10.3390/biomedicines13092086
“The median age at diagnosis is approximately 69 years, with over 60% of cases occurring in individuals aged 65 and older [4].”
Multiple Myeloma: A Continuously Evolving Disease
Mitra, P. (2025) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2025060495
Jagannath, S., Kharat, A. A., Chinaeke, E. E., Fu, A. Z., Perciavalle, M., Huo, S., & Qureshi, Z. P. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2583668 · Cited by 1
XGBoost algorithm constructs a new model to predict the nutritional risk of multiple myelomaPreprint
Gao, X., Liu, Y., Liu, Y., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7864042/v1
RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma
Wang, Y., Jia, Q., Liu, H., Li, Z., & Ma, Y. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04038-z
“One of the major clinical challenges with radiotherapy is the development of resistance, which makes the treatment ineffective in the long term [1–3].”
Strotmann, A., Leitner, T., Mazzeo, P., Evers, G., Pohlmann, A., Eisfeld, C., Seib, M., von Bubnoff, N., Lenz, G., Shumilov, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.008
Hu, C., Chen, W., Zhang, P., Shen, T., & Zhao, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1696768
“This phenomenon is mainly related to the accessibility of targeted drugs (35).”
Sharma, A., Pathangey, L. B., Chirackal, S. S., Shim, K. G., Fonseca, R., & Swaminathan, S. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70084
Hungria, V., Maiolino, Â., Magalhães, R., de Lacerda, M. P., Remaggi, G., Scibona, P., Seehaus, C. M., Brulc, E. B., Savoy, N., Fantl, D. B. E., et al. (2025) · Current Oncology · doi:10.3390/curroncol33010016
“Multiple myeloma (MM) is a plasma cell disorder that continues to pose a therapeutic challenge due to its relapsing and incurable nature [1].”
Chebykina, D., & Кробинец, И. И. (2026) · Clinical oncohematology · doi:10.21320/2500-2139-2026-19-1-96-103
Tu, S.-K., Yang, J., Min, S.-D., Fan, H., Hu, M. I.-N., Tian, J., Li, M., & Song, K. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1672927
“It ranks as the second most prevalent hematological malignancy in numerous countries and primarily affects the elderly, accounting for approximately 2% of cancer-related mortality, particularly in the United States, Australia, and Western Europe (13 – 16).”
Xi, X., Xu, R., Li, Y., Zhang, D., Sun, Y., Liu, Y., Du, X., Hao, Z., Wang, L., & Du, J. (2026) · BMC Women s Health · doi:10.1186/s12905-025-04228-7
“The determination of serum albumin and β−2 microglobulin in blood is of great value for the staging of diseases [5].”
Wu, L., Li, Y., & Li, H. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1578132
“Complications can exacerbate the disease, and adjustments in the treatment regimen can increase drug dosage and side effects, further aggravating physical discomfort and causing anxiety and depression (20 – 22).”
When Sarcoidosis Looks Like Myeloma: A Diagnostic Pitfall
Chen, A., Smith, K., Wu, R. I., et al. (2026) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2025.1000
Qin, L., Yin, Y. B., Wu, P., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1751926
Mechanism of action of isatuximab in multiple myeloma. Literature review and clinical observation
Soloveva, M. V., Solovev, M. V., & Менделеева, Л. П. (2026) · Oncohematology · doi:10.17650/1818-8346-2026-21-1-59-65
Wang, S.-X., Luo, T., Yang, N., Liu, X.-R., & Ma, Y.-P. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06923-3
Ismail, A., Ashfaq, S., Majeed, M. I., et al. (2026) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2026.103911
Chai, L., Guo, Y., He, L., 杨阿洛, Su, L., Wang, J., & Yang, J. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1784817
“Through real-world case-control analysis, this study confirmed advanced age as the most powerful risk factor for MM (50–69 years: aOR = 6.69; ≥ 70 years: aOR = 6.10), consistent with its well-established nature as an age-related malignancy (3, 16, 17).”
InfluentialIriuchishima, H., Saito, A., Mihara, M., Kanaya, S., Yoshizawa, R., Isoda, A., & Matsumoto, M. (2026) · Cancers · doi:10.3390/cancers18071048
“Multiple myeloma (MM) is one of the most common neoplastic diseases of older adults, with a median age at diagnosis of approximately 70 years, and over 60% of diagnosed patients are over 65 years of age [1].”
Botta, C., Colombo, G. L., Matteo, S. D., et al. (2026) · Cancers · doi:10.3390/cancers18071070
“MM accounts for approximately 2% of all cancers and 10% of hematologic malignancies [3], with real-world Italian data reporting an incidence of 9 new cases per 100,000 inhabitants and a prevalence of 40.9 cases per 100,000 [4].”
InfluentialThe Association Between Multiple Myeloma and Neuropsychiatric Manifestations: A Narrative Review
Block, M. M., Spaccarelli, L., Taghizadeh, C. S., Ertz-Archambault, N. M., Kowalik, J., & Thippaiah, S. M. (2026) · Psycho-Oncology · doi:10.1002/pon.70438 · Cited by 1
Holopainen, A., Lehto, H., Kuittinen, T., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70184
“MM is characterized by malignant plasma cell proliferation in bone marrow, leading to multiple symptoms including organ damage such as bone lesions and fractures, anemia, hypercal-cemia, and renal dysfunction [6, 8, 9].”
Evett, S., Kahl, A. R., Schmidt, M. E., et al. (2026) · Cancer Causes & Control · doi:10.1007/s10552-026-02166-9
“Exact reasons for our finding of lower myeloma survival in rural areas compared to urban areas are unknown, though may be attributable to differences in myeloma risk factors, such as age, race, sex or family history [36].”
Metadata
- Authors
- Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H.
- Affiliations
- Augusta University (US)
- Allegheny Health Network (US)
- Sovah Health Martinsville (US)
- Corresponding author
- Padala, Sandeep Anand
- ORCID
- Venue
- Medical Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-20
- Volume
- 9
- Issue
- 1
- Pages
- 3
- ISSN
- 2076-3271 (ISSN-L)
- PMC
- PMC7838784
- OpenAlex
- W3125352349
- Semantic Scholar
- f98f43b63e68b1a4fa37ed1682b10b64d590a291
- Cited by
- 332
- References
- 56
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 87 · 2023: 66 · 2022: 38 · 2021: 5
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medical Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, incidence and mortality trends, risk factors, M protein, International Staging System, beta2-microglobulin, lactate dehydrogenase, chromosomal abnormalities, hematopoietic stem cell transplantation, bisphosphonates, skeletal-related events, relapsed multiple myeloma, daratumumab, proteasome inhibitors, immunomodulating agents, CAR T-cell therapy, BCMA, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma
- MeSH terms
- Immunomodulating Agents, Anemia, Humans, Hypercalcemia, Multiple Myeloma, Pain, Paraproteinemias, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.